Stock Ratings / Health Care / IBIO / earnings

CNTB (35) GANX (41) PLRX (44) HOWL (47) ⌘ Pro Terminal →

iBio Inc. (IBIO) Next Earnings Date & Expected ±12.5% Move

Q: Where is IBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

IBIO last traded at $0.77 (-5.52% on volume of 214,298 shares), positioning the stock -28.70% below its 50-day simple moving average ($1.08) and -54.44% below its 200-day simple moving average ($1.69). Across its 52-week range of $0.69 to $3.82, IBIO sits at the 2.6% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.87).

Q: When is IBIO's next earnings date?

Based on SEC filing cadence, iBio Inc. (IBIO)'s next quarterly reporting window is estimated around Dec 28, 2026.

Q: How much is IBIO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for IBIO, spanning a range between $1 and $0.87.

$0.77 -5.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.76

iBio Inc. (IBIO) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $52.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IBIO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, iBio Inc. (NASDAQ: IBIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.77 (-5.52% 1D, market cap $52.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IBIO ranks #968 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IBIO compare to CNTB and GANX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IBIO carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CNTB (Connect Biopharma Holdings Limited) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $52.6M) and GANX (Gain Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $51.9M). Among the 5-stock peer group, IBIO leads on earnings multiple (N/A) while IBIO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IBIO?

▼

Per IBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001420720), iBio Inc. generated $400.0K in revenue (+77.8% YoY), -$18.4M in net income, and -$15.3M in free cash flow against $64.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.76 (-1.18%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IBIO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY IBIO SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (26% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (22% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.90-15.6% Next Q

Q2 (-2Q)

Grade E$0.76-6.6% Next Q

Q3 (-1Q)

Grade E$0.71+8.5% Next Q

Current

Grade E$0.77-11.1% Hist 90D α

Trajectory: E (31) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IBIO currently carries a cautious 23/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.08) and Max Pain ($0.81) forces dealer call-delta covering toward $4.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IBIO Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 28, 2026 (~55 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.10 Expected Swing

MODEL EARNINGS SETUP GAUGE

IBIO Quantitative Pre-Earnings Setup: 23/100

Trailing EPS: $4.25 • YoY Revenue Growth: 77.8%

Model Bullish Setup (23/100)Model Risk Weight (77/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-06-30	$400.0K	-$18.4M	-$15.3M	52%
FY 2024	2024-06-30	$225.0K	-$24.9M	-$18.8M	52%
FY 2023	2023-06-30	$0	-$65.0M	-$30.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IBIO)

✓Walkthrough of IBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.27%▼ DESCENDING CHANNEL

2026-11-02O $0.80H $0.81L $0.77C $0.77VOL 248.6K

RES: $1.19SUP: $0.60SMA50: $1.08SMA200: $1.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IBIO Butterfly Map → + Track IBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +77.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IBIO)

Health Care Rank #968 of 1016 ⚔️ CNTB vs IBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IBIO vs. CNTB, GANX, PLRX, HOWL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, iBio Inc. (IBIO) ranks #968 by composite RQD confidence (23/100, grade E) and #744 by equity capitalization ($52.3M). Within this direct 5-issuer industry benchmark cohort, IBIO leads on earnings valuation at N/A trailing P/E, while IBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. HOWL currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with IBIO at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IBIO ACTIVE iBio Inc.	E	23/100	—	—	-35.0%	-5.52%	$52.3M	Benchmark Subject
CNTB Connect Biopharma Holdings Limited	D-	35/100	—	—	-35.0%	-3.97%	$52.6M	/cntb-vs-ibio →
GANX Gain Therapeutics Inc.	D-	41/100	—	—	-35.0%	-5.04%	$51.9M	/ganx-vs-ibio →
PLRX Pliant Therapeutics Inc.	D	44/100	—	—	-35.0%	-0.13%	$53.3M	/plrx-vs-ibio →
HOWL Werewolf Therapeutics Inc.	D	47/100	—	—	-35.0%	-10.35%	$53.5M	/howl-vs-ibio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001420720

In its most recent audited fiscal period (FY2025, filed 2025-06-30), iBio Inc. (IBIO) reported GAAP revenue of $400.0K (+77.8% vs. FY2024 revenue of $225.0K ) , GAAP net income of -$18.4M, operating cash flow of -$15.3M, and free cash flow of -$15.3M (+18.4% YoY). On the balance sheet, IBIO closed FY2025 with $64.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$400.0K	-$18.4M	-$15.3M	-$15.3M	$64.4M	—
FY2024 (FY)	2024-06-30	$225.0K	-$24.9M	-$18.6M	-$18.8M	$21.7M	—
FY2023 (FY)	2023-06-30	$0	-$65.0M	-$30.4M	-$30.4M	—	—

3. IBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IBIO compare to CNTB and GANX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IBIO?

Where is IBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

IBIO last traded at $0.77 (-5.52% on volume of 214,298 shares), positioning the stock -28.70% below its 50-day simple moving average ($1.08) and -54.44% below its 200-day simple moving average ($1.69). Across its 52-week range of $0.69 to $3.82, IBIO sits at the 2.6% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.87).

IBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is IBIO's next earnings date?

Based on SEC filing cadence, iBio Inc. (IBIO)'s next quarterly reporting window is estimated around Dec 28, 2026.

How much is IBIO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for IBIO, spanning a range between $1 and $0.87.

Direct Sub-Reports: IBIO RQD Cockpit IBIO 12M Forecast IBIO Earnings & Move IBIO Dividends & DRIP IBIO Insiders & 13F IBIO Whale Options IBIO Profit Sankey IBIO News & Why

ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IBIO — iBio Inc.: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline

As of: 2026-11-02T14:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, iBio Inc. (IBIO) carries a composite score of 23/100 (E — Roarable Strong Sell — Forensic Risk / Avoid) at a current price of $0.77 (-5.52%). Fundamental cash generation scores 3/20 (ROIC -35.0%, FCF yield —), institutional 13F whale accumulation scores 4/20, insider conviction scores 5/20, macro regime alignment scores 6/20 (Beta 1.00), and forensic balance-sheet protection scores 5/20 (Altman Z-Score 0.20, Piotroski F-Score 4/9).

Investor Implication: At current trailing P/E and current forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (-60.0%) and free cash flow conversion relative to the 52-week range of $0.69 – $3.82.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), IBIO is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

IBIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for iBio Inc. (IBIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IBIO Debate Forum (3) ↓

🟢 CATALYST Benzinga • 4d ago

Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor

There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out whether the shares

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 13d ago

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 20d ago

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610 in f

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 20d ago

iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity

In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human trials of IBIO-610 in

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 61d ago

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, toda

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 66d ago

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 124d ago

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and t

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 143d ago

Could iBio (IBIO) Be an Underrated Obesity Stock?

With 16 hedge funds having stakes in the stock, iBio, Inc. (NASDAQ:IBIO) is among the 10 Under-the-Radar AI Stocks to Buy in 2026. On June 8, Raymond James initiated coverage of iBio, Inc. (NASDAQ:IBIO) with an Outperfor

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IBIO Bull vs. Bear Conversation Board — What's Your Call at $0.77?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IBIO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.71 (-12.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IBIO (E • RQD 23/100) a Buy at $0.81?

Welcome to the IBIO (iBio Inc.) Roar Pit. Current RQD Composite is 23/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.62 (-23.5%)

Spot @ $0.81

Pump the brakes on IBIO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IBIO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless iBio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.98 (+21.0%)

Spot @ $0.81

IBIO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IBIO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.81 (52-wk range $0.69 - $3.82), any beat on forward guidance forces shorts and underweight funds to chase.